Efficacy Evaluation
Service Overview
Acer Biosciences possesses profound scientific expertise in oncology, immunology, neuroscience, cardiovascular & metabolic diseases, fibrosis, and infectious diseases. We provide global clients with deeply customized solutions spanning target research, drug discovery, druggability assessment, and IND submission, accelerating the preclinical development of candidate drugs through systematic efficacy evaluation services.
Oncology Efficacy Evaluation
Animal Model Resources
1.Syngeneic Models
Mouse Syngeneic Models: B16, MC38, CT26, etc.
Genetically Humanized Mouse Models: B-h4-1BB, B-hPD-1, B-hCD40, B-hCD3, B-hCD28, etc.
2.Xenograft Models
CDX/PDX Models/Hematologic
Cell Bank Resources
(1)Human Tumor Cell Lines
Lung Cancer (38 lines): A549, HCC827 (EGFR del), NCI-H1299, PC-9, NCI-H460, etc.
Colorectal Cancer (23 lines): HCT-116, HT-29, SW480, COLO 205, DLD-1, etc.
Gastric Cancer (12 lines): NCI-N87, MKN-45, AGS, etc.
Breast Cancer (15 lines): MCF-7 (ER+), MDA-MB-231 (TNBC), BT-474 (HER2+), etc.
Lymphoma/Leukemia (32 lines): Raji, Daudi, Jurkat, HL-60, THP-1, MOLM-13, etc.
Others: Liver cancer, pancreatic cancer, ovarian cancer, prostate cancer, glioblastoma, etc.
(2)Murine Syngeneic Cell Lines
Breast Cancer: 4T1 (BALB/c), EO771 (C57BL/6)
Colorectal Cancer: MC38, CT26 (BALB/c)
Lung Cancer: LLC (C57BL/6)
Melanoma: B16-F10 (C57BL/6)
Lymphoma: A20 (BALB/c)
Others: Hepa1-6 (liver cancer), Pan02 (pancreatic cancer), MB49 (bladder cancer)
(3)Fluorescent/Luminescent-labeled Cell Lines
Lung Cancer: A549-luc, HCC827-luc, NCI-H1975-luc
Breast Cancer: MDA-MB-231-luc, 4T1-luc
Colorectal Cancer: HCT-116-luc, CT26-luc
Glioma: U87MG-luc, U251-luc
(4)High Metastatic Potential Cell Lines
Brain Metastasis: MDA-MB-231, JIMT-1, HCC827
Bone Metastasis: MDA-MB-231, PC-3, NCI-N87
Liver Metastasis: HCT-116, HT-29
(5)Drug-Resistant Cell Lines
Lung Cancer: A549/cDDP (cisplatin-resistant), HCC827/GR (gefitinib-resistant)
Breast Cancer: MCF7/ADR (doxorubicin-resistant)
Colorectal Cancer: HCT-8/5-FU (5-fluorouracil-resistant)
Oncology Efficacy Evaluation System
1.Pharmacodynamic Endpoints
Tumor volume monitoring & growth kinetic analysis / Survival analysis / Tumor Growth Inhibition (TGI) / Tumor weight & histopathological assessment.
2.Molecular & Cellular Level Assays
Protein Expression: Western Blot, Immunohistochemistry (IHC), Multiplex Immunofluorescence (mIHC).
Gene Expression Analysis: qPCR, RNA-seq.
Cellular Function Assays: Apoptosis, cell cycle, migration, invasion, etc.
3.Tumor Microenvironment Analysis
Flow Cytometry: Immune cell phenotyping and infiltration analysis.
Cytokine & Metabolite Detection: ELISA, MSD, ELISPOT platforms.
Functional characterization of Tumor-Associated Macrophages (TAMs), T cell subsets, etc.
4.Imaging Evaluation Platforms
Small Animal In Vivo Imaging Systems (Fluorescence/Bioluminescence) / High-resolution Microscopy (Tissue/Cellular) / Structural/Functional Imaging: Micro-CT, PET-CT.
Immunology & Inflammatory Diseases Efficacy Evaluation
The relevant models are as follows:
Multiple Sclerosis (Mice/Rats)
Systemic Lupus Erythematosus (Mice/Rats)
Hypersensitivity (Mice/Rats)
Rheumatoid Arthritis (RA) (Rats, Rabbits, Dogs)
Psoriasis (Mice/Rats)
Atopic Dermatitis (Mice)
Asthma Attack (Guinea Pigs)
Alopecia Areata (Mice)
Ulcerative Colitis (Rats)
Transplantation Immunology (Mice)
Paw Edema (Mice/Rats)
Ear Edema (Mice/Rats)
Pneumonia Models (Mice/Rats)
Guillain-Barré Syndrome (Mice)
Cardiovascular & Cerebrovascular Diseases Efficacy Evaluation
The relevant models are as follows:
MCAO Model (Reperfusion/Permanent) (Mice/Rats)
Hemorrhagic Transformation Model (Rats)
Traumatic Brain Injury (TBI) Model (Rats)
Myocardial Hypertrophy/Heart Failure Model (Mice/Rats, Dogs, NHPs)
Myocardial Ischemia/Myocardial Infarction Model (Rats, Dogs, NHPs)
Arrhythmia Model (Mice/Rats, Rabbits)
Pulmonary Embolism Model (Dogs, NHPs)
Common Carotid Artery Stenosis Model (Mice/Rats, Dogs, NHPs)
FeCl₃-induced Thrombosis (Rats, Rabbits)
Vascular Calcification Model (Rats)
Hypertension Model (Mice/Rats)
Anemia Models (Renal, Iron Deficiency, Aplastic, Hemolytic, etc.) (Mice/Rats)
Neurological Diseases Efficacy Evaluation
The relevant models are as follows:
Parkinson's Disease (PD) Model (Mice/Rats)
Alzheimer's Disease (AD) Model (Mice)
Spinal Cord Injury Model (Rats)
Sciatic Nerve Injury Model (Rats)
Attention Deficit Hyperactivity Disorder Model (Rats)
Epilepsy Model (Rats)
Insomnia Model (Dogs, NHPs)
Convulsion Model (Rats)
Depression Model (Mice/Rats)
Neonatal Hypoxic-Ischemic Encephalopathy Model (Rats)
Metabolic Diseases Efficacy Evaluation
The relevant models are as follows:
Non-alcoholic Fatty Liver Disease (Mice/Rats)
Gout (Rats)
Hypothyroidism Model (Mice/Rats)
Hyperthyroidism Model (Mice/Rats)
Diabetes (Mice/Rats, Pigs)
Uremia (Rats)
Liver Cirrhosis (Mice/Rats)
Sepsis (Mice/Rats, Rabbits)
Liver Fibrosis (Mice/Rats)
Osteoporosis (Rats)
Pain Efficacy Evaluation
The relevant models are as follows:
Inflammatory Pain: Complete Freund's Adjuvant, Formalin Paw, Capsaicin
Post-traumatic Analgesia: Plantar Incision Pain
Peripheral Neuropathic Pain: Diabetic Foot Pain, SNL Neuropathic Pain
Visceral Pain: Acetic Acid Writhing Model
Other Efficacy Evaluations
The relevant models are as follows:
Burn/Scald Model (Mice/Rats)
Depression Model
Skin Scar Model (Rats, Rabbits)
Acne Model (Mice/Rats, Rabbits)
Dry Eye Syndrome (Mice/Rats)
Glaucoma (Chinchilla Rabbits)
Cataract (Rats, Rabbits)
